• SeaStar Medical reported post-approval findings linking QUELIMMUNE to significantly higher survival in critically ill children with sepsis-associated acute kidney injury.
• Results presented today at ASN Kidney Week 2026 showed improved survival versus a historical comparator in the primary analysis.
• No device-related adverse events occurred among treated registry patients.
• The exploratory observational study supports an association with improved outcomes, rather than establishing a causal treatment benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221201PRIMZONEFULLFEED9851028) on October 22, 2026, and is solely responsible for the information contained therein.